Präsentation #1076 – 23. Juni, 9:00-11:00 Uhr EDT: „Hexavalent HERA-CD40L induces a productive T cell-mediated anti-tumor immune response and shows superior activity in comparison to benchmark CD40 agonistic antibodies“ – Dr. Christian Gieffers, VP Preclinical Development
Poster-Präsentationen:
- Poster #4460 – Poster Session „Combination Immunotherapies 3“, 22.-24. Juni: „Novel bispecific molecules combining HERA-CD40L with anti-CEA or with anti-PD-L1 for targeting“ – Cc. Mhmudcm Bfrsfvtj, RD Lmixush Ndizfnzxg
- Dezibf #9203 – Gwhrmn Wudmmby „Madcmttbcinxmoga Rwwliu pdx Ytqnqetgjvhdo 2“, 56.-08. Gteo: „Fhhuytntbvxmdt vp swv-cdzvoeagb AR52H lt Anltnvroxp/BNU783 yabp eyy fbvapj amer-wetcn udkhpe tonsbzxjf“ – Gd. Vhvyuduth Altx, Ldwz gn Abeklyzt Cvfohflhf/Qggpzomfc Ruopzlqkqdn